Page last updated: 2024-09-05

erlotinib hydrochloride and Adenocarcinoma, Papillary

erlotinib hydrochloride has been researched along with Adenocarcinoma, Papillary in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Masago, K; Mishima, M; Miura, M; Togashi, Y; Toyama, Y	1

Other Studies

1 other study(ies) available for erlotinib hydrochloride and Adenocarcinoma, Papillary

Article	Year
Good clinical response to erlotinib in a patient with anaplastic thyroid carcinoma harboring an epidermal growth factor somatic mutation, L858R, in exon 21. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jun-01, Volume: 29, Issue:16 Topics: Adenocarcinoma, Papillary; Aged; Antineoplastic Agents; Carcinoma, Signet Ring Cell; DNA Mutational Analysis; Epidermal Growth Factor; Erlotinib Hydrochloride; Exons; Female; Humans; Immunohistochemistry; Mutation; Polymerase Chain Reaction; Quinazolines; Thyroid Neoplasms	2011

Article

Year

Good clinical response to erlotinib in a patient with anaplastic thyroid carcinoma harboring an epidermal growth factor somatic mutation, L858R, in exon 21.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jun-01, Volume: 29, Issue:16

Topics: Adenocarcinoma, Papillary; Aged; Antineoplastic Agents; Carcinoma, Signet Ring Cell; DNA Mutational Analysis; Epidermal Growth Factor; Erlotinib Hydrochloride; Exons; Female; Humans; Immunohistochemistry; Mutation; Polymerase Chain Reaction; Quinazolines; Thyroid Neoplasms

2011